Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling.
Bone disease in patients with multiple myeloma (MM) is characterized by uncoupled bone remodeling, evident as enhanced osteolytic resorption and decreased rather than increased bone formation. MM-triggered osteolysis follows deregulation of the receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin cytokine axis. Inhibition of bone formation may result from the ability of MM to inhibit the function of Wnts, secreted glycoproteins critical to osteoblast development. Recent studies show how these processes may be linked.
Pearse
Roger N
RN
Division of Hematology/Oncology, Cornell University Medical College, New York, New York 10021, USA. rnp2001@med.cornell.edu
D000818:Animals; D016723:Bone Remodeling / Q000502:physiology*; D006801:Humans; D009101:Multiple Myeloma / Q000503:physiopathology*; D053244:Osteoprotegerin / Q000096:biosynthesis; D053245:RANK Ligand / Q000096:biosynthesis; D015398:Signal Transduction / Q000502:physiology*; D051153:Wnt Proteins / Q000037:antagonists & inhibitors*
D053244:Osteoprotegerin; D053245:RANK Ligand; D051153:Wnt Proteins